5 results
The primary objective of this study is to observe the long-term efficacy, safety, and tolerability of repeated administration of Upadacitinib (ABT-494) in subjects with Crohn's disease (CD) who completed Study M13-740.
To determine the microbiological and clinical cure rate after 14 days.
To evaluate the safety and efficacy of multiple doses of ABT-494 (Upadacitinib) monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis.
To evaluate the Long-Term Safety and Efficacy of upadacitinib.
Main objective of SS1 (Ph2b induction) is to characterize dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission defined by Adapted Mayo score in subjects with moderately to severely active ulcerative…